Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction.

Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A.

JACC Heart Fail. 2013 Feb;1(1):40-7.

2.

Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study.

Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A.

Eur J Heart Fail. 2012 Oct;14(10):1179-88. Epub 2012 Jul 3.

3.

Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.

Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA, Peterson ED.

J Am Heart Assoc. 2016 Jan 21;5(1). pii: e002612. doi: 10.1161/JAHA.115.002612.

4.

Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.

Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH.

JAMA. 2012 Nov 28;308(20):2097-107. doi: 10.1001/jama.2012.14795.

PMID:
23188026
5.

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

Mujib M, Patel K, Fonarow GC, Kitzman DW, Zhang Y, Aban IB, Ekundayo OJ, Love TE, Kilgore ML, Allman RM, Gheorghiade M, Ahmed A.

Am J Med. 2013 May;126(5):401-10. doi: 10.1016/j.amjmed.2013.01.004. Epub 2013 Mar 16.

6.

Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data.

Zhang Y, Kilgore ML, Arora T, Mujib M, Ekundayo OJ, Aban IB, Feller MA, Desai RV, Love TE, Allman RM, Fonarow GC, Ahmed A.

Int J Cardiol. 2013 Jun 5;166(1):230-5. doi: 10.1016/j.ijcard.2011.10.089. Epub 2011 Nov 25.

7.

Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.

Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, Kitzman DW, Gheorghiade M, Allman RM, Ahmed A.

Int J Cardiol. 2014 May 15;173(3):393-401. doi: 10.1016/j.ijcard.2014.03.005. Epub 2014 Mar 11.

8.

Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction.

Patel K, Fonarow GC, Ahmed M, Morgan C, Kilgore M, Love TE, Deedwania P, Aronow WS, Anker SD, Ahmed A.

Circ Heart Fail. 2014 Nov;7(6):945-52. doi: 10.1161/CIRCHEARTFAILURE.114.001301. Epub 2014 Oct 8.

9.

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.

Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2014 Sep;7(5):740-51. doi: 10.1161/CIRCHEARTFAILURE.114.001583. Epub 2014 Aug 13.

10.

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials.

Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J.

BMC Med. 2015 Jan 19;13:10. doi: 10.1186/s12916-014-0261-8.

11.

Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.

Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.

J Card Fail. 2012 Apr;18(4):265-81. doi: 10.1016/j.cardfail.2012.02.005.

PMID:
22464767
12.

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.

Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA; TOPCAT Investigators.

Circ Heart Fail. 2016 Mar;9(3):e001937. doi: 10.1161/CIRCHEARTFAILURE.114.001937.

13.

Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort.

Hoong CW, Lim CP, Gao F, Chen Q, Kawa LB, Ching CK, Sim DK.

J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):583-90. doi: 10.2459/JCM.0000000000000100. Review.

PMID:
25022929
14.

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA.

Am Heart J. 2011 Dec;162(6):966-972.e10. doi: 10.1016/j.ahj.2011.09.007. Epub 2011 Nov 8.

PMID:
22137068
15.

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals.

J Am Coll Cardiol. 2007 Aug 21;50(8):768-77. Epub 2007 Aug 6.

16.

Use of aldosterone antagonists in heart failure.

Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC.

JAMA. 2009 Oct 21;302(15):1658-65. doi: 10.1001/jama.2009.1493.

PMID:
19843900
17.

Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, PiƱa IL, Whellan DJ, O'Connor CM.

J Card Fail. 2014 Jan;20(1):38-44. doi: 10.1016/j.cardfail.2013.11.011. Epub 2013 Dec 1.

18.

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B.

Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.

19.

In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.

Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L; IN HF Outcome Investigators.

Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22.

PMID:
24630337
20.

Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.

Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM.

Circ Heart Fail. 2016 Apr;9(4):e002763. doi: 10.1161/CIRCHEARTFAILURE.115.002763.

Supplemental Content

Support Center